Drug Royalty II was formed to acquire shares in the royalties of
drug sales from pharmaceutical and biotechnology companies,
research institutions, universities and inventors. In
March 2010, Drug Royalty II achieved an oversubscribed final close
with over $701 million of capital commitments.
DRI Capital is a Toronto-based global leader in healthcare
investing. Established in 1992, DRI Capital pioneered royalty
monetization as a commonly accepted option for owners of